Acrivastine, typically administered at 8 mg three times daily, is recognized as an effective and well-tolerated antihistamine for managing chronic urticaria and allergic rhinitis. It has proven to be more effective than a placebo and similarly effective as clemastine or terfenadine in treating seasonal allergic rhinitis. In dermatoses where histamine plays a pathogenetic role, acrivastine's efficacy surpasses that of a placebo and matches that of standard doses of clemastine, hydroxyzine, chlorpheniramine, cyproheptadine, and terfenadine. Notably, acrivastine is less likely to cause drowsiness compared to clemastine, and its adverse effects are comparable to those associated with a placebo or terfenadine^[1].

Both 4 mg and 8 mg doses of acrivastine significantly alleviate symptoms of seasonal allergic rhinitis, with notable improvements in symptom scores for sneezing, runny nose, and overall symptoms. The 8 mg dose additionally reduces symptom scores for watery eyes and itchy throat, affirming acrivastine's effectiveness and tolerability in treating seasonal allergic rhinitis^[2].